Heart failure is amongst the leading causes of mortality and morbidity in India in spite of currently available treatment options. There is a significant need to improve the lives of Heart failure patients. SGLT2i class of drug particularly Dapagliflozin has shown superiority in lowering cardiovascular death and hospitalization due to heart failure vs Placebo. This becomes even more relevant in the current pandemic of COVID-19 when there is an increase in the risk of mortality in patients with pre-existing cardiovascular diseases.
In this regard, AstraZeneca and Docplexus have organized an interactive webinar on 7 th May 2020 at 5:00 PM . In this webinar session, Dr. Abraham Oomman and Dr. Upendra Kaul will talk about " DECLARE to DAPA HF: Key milestone in HF Management ." Agenda: We invite you to submit your questions which will be answered by the…
